Continuous Glucose Monitoring MarketSize, Share & Industry Analysis, 2026-2034By ComponentBy Product TypeBy Sensor Wear DurationBy Sensing TechnologyBy ApplicationBy Age GroupBy Connectivity and IntegrationBy End UserBy Distribution ChannelBy Reimbursement Status
Full title & scope — all 10 axes with their segments
Continuous Glucose Monitoring Market Size, Share & Industry Analysis, By Component (Sensors, Transmitters, Receivers and Readers, Software and Data Platforms, Insertion and Accessories), By Product Type (Real-Time CGM, Intermittently Scanned CGM, Professional CGM, Over-the-Counter CGM), By Sensor Wear Duration (Up to 7 Days, 8 to 10 Days, 11 to 15 Days, Beyond 15 Days), By Sensing Technology (Minimally Invasive Enzymatic Electrochemical, Implantable Fluorescence-Based, Non-Invasive, Microneedle-Based), By Application (Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes, Prediabetes and Metabolic Health, Hospital Glycemic Management), By Age Group (Pediatric, Adult, Geriatric), By Connectivity and Integration (Standalone CGM, Integrated with Insulin Pumps, Integrated with Smart Pens, Open-Source and Third-Party Integrated), By End User (Home Care Settings, Hospitals, Clinics and Endocrinology Centers, Ambulatory Surgical and Long-Term Care Facilities, Research and Clinical Trial Organizations), By Distribution Channel (Retail Pharmacies, Online Pharmacies and E-Commerce, Direct-to-Consumer / Manufacturer Direct, Durable Medical Equipment Suppliers, Hospital Pharmacies), By Reimbursement Status (Public Insurance Reimbursed, Private Insurance Reimbursed, Out-of-Pocket), and Regional Forecast, 2026-2034
How the estimates were built: data sources, modelling approach and validation steps.
Research approach
A market size is a claim about the world, and a claim is only as good as the route to it. Every study is built upward from units and prices — what is actually produced, sold or performed, at what it actually changes hands for — rather than from a headline figure divided downwards. Disclosed company revenue is then used to check that build, not to produce it.
The size is built upward from the number of people using a continuous sensor and what each user spends in a year. Active users by diabetes type and care setting are multiplied by sensors consumed per user per year and by the realised net price per sensor after rebates and channel margins, with transmitter, reader, software and accessory revenue added on the installed base. That build is then checked against disclosed segment revenue of the listed manufacturers and against public reimbursement spending on glucose monitoring supplies. Where the two disagree, the bottom-up assumption is corrected, usually wear days per sensor, net price or user counts, and the disclosed revenue stays as the reference.
The four stages
The same sequence runs behind every published study, whatever the industry. The order matters as much as the steps: the segment axes are fixed before any number is collected, so the model is never reshaped to fit whatever data happens to turn up.
What the build rests on, and what checks it
The two are not interchangeable. The left column produces the number; the right column tests it. When the check disagrees with the build, the answer is to find which bottom-up assumption is wrong — a unit count, a price, a take-up rate — not to split the difference between them.
- Volume actually transacted — units produced, installed, dispensed or procedures performed, counted at the level each is genuinely recorded
- Realised pricing by tier and channel, rather than one blended average applied across the whole market
- Take-up and frequency: how much of the addressable base buys, and how often it repeats
- Disclosed revenue of the companies serving the market, where filings separate it far enough to be usable
- Buyer-side spending totals — capital budgets, procurement lines, or the output of the end market the product is bought against
- Trade and customs flows, where the product crosses borders in a separately recorded form
Data sources
Published data establishes what happened. Only the people transacting in a market can say why, and what is about to change — so the two are collected separately and weighted differently.
- Commercial and product leadership at the companies that supply the market
- Procurement and specification leads at the organisations that buy it
- Distributors, integrators and channel partners, where the market is served indirectly
- Regulatory and standards specialists, where approval governs what can be sold at all
- Company filings, annual reports and investor disclosure
- Government statistics, customs records and regulatory registers
- Trade association output and standards-body publications
- Technical and peer-reviewed literature, where the market rests on a clinical or engineering claim
Interviews are directed at the roles that decide what is prescribed, stocked and paid for in continuous glucose monitoring: endocrinologists and diabetes educators, hospital and clinic procurement leads, pharmacy and durable medical equipment buyers, payer and reimbursement policy staff, and product, regulatory and commercial managers at device makers. Sampling emphasises North America, Europe, Japan, China and India, where coverage rules and device mix differ the most, and adds contacts in the Gulf states and Brazil to test emerging demand. Responses are used to test unit prices, wear patterns, prescribing mix and coverage assumptions, not to set the market total.
Desk research rests on the US FDA 510(k), De Novo and premarket approval listings for glucose monitoring devices, the European Union's EUDAMED device database, Japan's PMDA approvals and China's NMPA registration records. Coverage and payment terms are read from the US Medicare DMEPOS fee schedule and local coverage determinations, and from national tariff lists in major European markets. Prevalence comes from the International Diabetes Federation Diabetes Atlas and national health surveys. Company annual reports, 10-K and 20-F filings and investor presentations supply segment revenue and user disclosures, and customs trade statistics for glucose monitoring instruments are used for cross-border flows.
Desk research runs across proprietary research databases including Factiva, OneSource and Hoovers alongside the public sources above. Modelling and statistical validation are run in SAS and SPSS.
Forecasting
The forecast is not a growth rate applied to a base year. It is built from the drivers that are expected to change, each one stated so a reader can disagree with it.
The forecast projects users first, then sensors per user and net price. User growth follows diabetes prevalence, earlier diagnosis and wider coverage for people with Type 2 diabetes who use basal insulin or non-insulin therapies, with a slower layer of over-the-counter adoption. Wear duration moves toward longer sensors, which lowers sensors per user, while price per day falls modestly in competitive tenders. Integration with insulin pumps and pens supports retention. For the forecast to hold, coverage must keep widening among the largest payers, accuracy must stay stable as wear time extends, and supply must keep pace with the demand that coverage creates.
Triangulation and validation
No figure enters a report on the strength of one source. Where the two sizing routes disagree the difference is not averaged away — the assumption causing it is isolated, tested against a third independent measure, and either corrected or carried forward as a stated limitation. Historical years are back-tested against the growth actually recorded before any forecast is allowed to run forward from them.
Growth from 2020 to 2025 was back-tested by running the same user, usage and price model on earlier years and comparing it with reported manufacturer revenue; assumptions were adjusted until the difference sat inside the tolerance set for the report. Segment shifts, such as the move toward longer wear and over-the-counter sales, were reviewed with industry experts. Sensitivities tested include coverage expansion among the largest payers, a faster fall in net price per day, and a delay in non-invasive sensing reaching the market. Regional and country figures were reconciled so each level sums to the one above it.
Confidence and limitations
Where an estimate is firm and where it is not is stated rather than left to be inferred from the precision of the number.
Confidence is strongest for sensors, real-time systems, Type 1 diabetes and the United States, where manufacturers and payers publish usable figures. It is weaker for professional CGM, hospital glycemic management, non-invasive sensing, and markets where private payment and informal channels hide volumes, including parts of Asia Pacific, Latin America and the Middle East and Africa. The 2025 total sits within a band of plus or minus 12 percent around the stated figure. A change in large payer coverage, a safety action on a widely used sensor, or a faster price decline would each force a revision.
Questions This Report Answers
6 questionsWhat is the market size and growth rate, globally and by region?
How is the market segmented, and which segments lead?
Which regions and countries are covered, and how do they compare?
What are the key drivers, restraints, opportunities and challenges?
Who are the leading companies operating in this market?
What trends are expected to shape the market through the forecast period?
Frequently Asked Questions
01What is the Continuous Glucose Monitoring Market projected to reach?
USD 36 USD Billion by 2034, CAGR 11.47%
02What years does this report cover?
Study period 2020–2034, base year 2025, historical data 2020-2024, forecast period 2026-2034.
03Which regions are covered?
North America, Europe, Asia Pacific, Latin America, Middle East and Africa.
04Which region accounted for the largest market share?
North America leads with 45% of global revenue through 2034.
05Which segment leads the market?
Sensors is the largest line by Component, at 52% of revenue in 2025.
06Who are the key companies profiled?
Dexcom, Inc., Abbott Laboratories, Medtronic plc, F. Hoffmann-La Roche Ltd, Senseonics Holdings, Inc., Insulet Corporation, Tandem Diabetes Care, Inc., Ascensia Diabetes Care Holdings AG, LifeScan, Inc., Sinocare Inc., Medtrum Technologies Inc., Roche Diabetes Care GmbH, i-SENS, Inc., Glucotrack, Inc., Biolinq, Inc., Embecta Corp., Terumo Corporation, Yuwell Medical (Jiangsu Yuyue Medical Equipment & Supply Co., Ltd.), Microtech Medical (Hangzhou) Co., Ltd., Ypsomed Holding AG, Diabeloop SA, Trividia Health, Inc., Nemaura Medical Inc., Dexcom Europe / Eversense partner Ascensia, Meiqi / Shenzhen Silicon Biotech Co., Ltd., Glucomen / A. Menarini Diagnostics S.r.l., Sibionics (Shenzhen Sibionics Technology Co., Ltd.). Full profiles are part of the paid report.
07Can the segmentation be customized?
Yes. Custom data cuts by geography, segment, or competitor set are available on request.
Why choose CDI
Need this report shaped around your question?
The scope isn't fixed. Tell us what your team needs that the standard edition doesn't cover, and an analyst will come back on what can be adjusted and how long it takes, before you commit to anything.
Most licences include 30–60 hours of customization at no extra cost. See what each licence includes
Additional Companies
Add competitors, suppliers or the peer set you benchmark against to the companies already covered.
Deeper Competitive View
Sharpen the landscape work around your own position: product line, channel, or a named shortlist of rivals.
Extra Segment Splits
Break the market down along an axis the standard scope doesn't cut it by, or go a level deeper inside one.
Application Focus
Narrow the analysis to the specific use cases and end users your team actually sells into.
Different Time Frame
Move the base year, or widen the historical and forecast windows the study is built on.
Country-Level Detail
Go below region level into the individual countries that matter to you, rather than the standard geography split.